Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Scleroderma is a chronic autoimmune disease characterized by hardening of the skin and internal organs.
• Progressive and refractory scleroderma cases present significant treatment challenges.
• Current treatment options offer limited efficacy for advanced disease stages.

Observation:

• Two patients with progressive, refractory scleroderma were treated with a sequential immunotherapy regimen.
• The regimen involved plasmapheresis, followed by rituximab, and then intravenous allogeneic umbilical-cord-derived mesenchymal stem cells (MSCs).
• Patients experienced subjective and objective improvements lasting over a year.

Findings:

• The combined immunotherapy approach demonstrated significant efficacy in both patients.
• Following disease recurrence, treatment with allogeneic MSCs alone also yielded a very good response.
• The treatment regimen was well-tolerated, with no significant adverse events reported.

Implications:

• This combined immunotherapy, particularly the use of allogeneic MSCs, shows promise for treating severe scleroderma.
• The findings support the potential of mesenchymal stem cell therapy in autoimmune conditions.
• Further large-scale studies are warranted to validate these promising results in a broader scleroderma population.